Gina Mentzer, MD
Cardiovascular Disease · Lincoln, NENPI 1316168628
Payments from drug & device makers
Across 322 payments — averaging $136.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$17K
- American Regent$15K
- Boston Scientific$7K
- E.r. Squibb & Sons, L.L.C.$420
- Actelion Pharmaceuticals US, Inc.$398
- Pfizer$334
- plus $3K from 38 others
What the payments were for
- Consulting fees$3,18012%
- Speaking & faculty fees$16,63062%
- Travel & lodging$1,3155%
- Food & beverage$5,59121%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$14,310
- Watchman$5,500
- GENERAL - THERAPIES$1,096
- WATCHMAN FLX$149
- UPTRAVI$123
- OPSUMIT$123
How this compares
$43,840 in reported general payments places this provider in the 80th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $98,340 |
| XareltoRivaroxaban | 70 | $64,026 |
| EntrestoSacubitril/Valsartan | 38 | $30,605 |
| JardianceEmpagliflozin | 31 | $25,661 |
| FarxigaDapagliflozin Propanediol | 25 | $18,623 |
| Repatha SureclickEvolocumab | 16 | $12,506 |
| Flecainide Acetate | 131 | $3,196 |
| Torsemide | 144 | $2,939 |
| Ranolazine ErRanolazine | 32 | $2,831 |
| Metoprolol Succinate | 363 | $2,706 |
| Amiodarone Hcl | 117 | $1,581 |
| Midodrine Hcl | 40 | $1,517 |
| Potassium Chloride | 79 | $1,418 |
| Carvedilol | 175 | $1,399 |
| Ezetimibe | 38 | $1,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $334 | $98,340136 claims |
| Johnson & JohnsonXarelto | $258 | $64,02670 claims |
| NovartisEntresto | $17,071 | $30,60538 claims |
| Boehringer IngelheimJardiance | $326 | $25,66131 claims |
| AstraZenecaFarxiga | $140 | $18,62325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Lincoln
- Robert PercellLincoln$1.3M
- Steven KruegerLincoln$840K
- Chad TraversLincoln$594K
- Keith MillerLincoln$204K
- John SteuterLincoln$190K
- Anuj JainLincoln$90K
- Wynn HunterLincoln$46K
- Omar NassLincoln$19K
- Rajeev AnchanLincoln$7K
- Kaliprasad AyalaLincoln$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.